Compared with TNF inhibitors, IL-23 inhibitor exposure was associated with significantly lower risk of paradoxical eczema; this result may have been attributable mostly to guselkumab due to the low number of exposures to other IL-23 inhibitors in these data. This evidence concerns the gene IL37 and Eczematoid dermatitis.